Series I. Correspondence
Biographical data (2), correspondence, 1976-81
Correspondence, 1974-76 (21-25); reviews (27), lectures and meetings (29-35), pending talks (36), graduate programs (37-39), Dean's memos (40), courses taught 1976-79 (41), examinations (42-44), biostatistics (45), clinical pharmacy (46), pathology 135 (47), pharmaceutical chemistry 120-212 (47-52).
Pharmaceutical chemistry 213-220 (53-60), pharmacology 135-140 (61-64), pharmacy 111-180.1 (65-83), pharmacy 454-475 (84-87), pharmacy administration 111-155 (89-90), physiology 125 (91), Academy of Pharmaceutical Sciences (92-95).
Academy of Pharmaceutical Sciences (cont.) dissolution testing (96-102), American Academy Clinical Chemistry (103), American Assoc. College of Pharmacy (104-05), American Pharmacy Association (106), Animal Care (107-108), California State Board of Pharmacy (115), Clinical Pharmacokinetics Laboratory (118), Drug Studies Unit (119-126).
Drug Studies Unit (cont.) (127), EPA (128), Federal Drug Administration (129-139), pharmaceutical companies correspondence: Abbott Laboratories to Forest Laboratories (140-159).
Pharmaceutical companies correspondence (cont.): Herbert Laboratories to Stanford Research Institute.
Pharmaceutical companies correspondence (cont.): Syntex to Upjohn (195-205), pharmacokinetics studies (210-224), Proprandiol (212-213), protocols in development (214), radiopharmaceuticals (216)
Miscellaneous drug studies: alprenolol to Misodiazole (217-242), financial ledgers (244-246), Journal of Pharmaceutical Sciences (247), Plenum Publishers (248-250.
Quinidine studies: correspondence, quarterly reports (251-260).
Quinidine studies: laboratory reports, graphs, patient studies..
Diphenylhydantoin (DPA studies) (263-277)
Theophyllin studies (278-86)
School of Pharmacy faculty--committee meetings minutes, Clinical Pharmacokinetics Laboratory, Pharmacology Technology Laboratory, manuscripts.